제대혈 채취 후 유로키나제의 첨가가 제대혈 적혈구 제거시 조혈모세포의 수득률에 미치는 영향

이영호,박현우,이영아,한훈,김경희,한진영 대한조혈모세포이식학회 2000 대한조혈모세포이식학회지 Vol.5 No.1

목적:제대혈 채취 후 24시간이 경과하여 적혈구를 제거하는 경우에 제대혈내의 응고계 및 섬유소 융해계의 변화로 인하여 clumping이나 미세혈전 등이 생겨 유핵세포나 CD34+ 세포의 수득률이 감소될 수 있다. 따라서 비록 항응고제가 처리된 제대혈이라 할지라도 제대혈 분리 전에 urokinase를 첨가하면 조혈모세포의 수득률을 높일 수 있을 것으로 생각된다. 그러나 현재까지 이에 대한 연구가 전혀 없는 상태이므로, 본 연구에서는 시간이 경과된 제대혈에 urokinase를 첨가하는 것이 효과가 있는지, 있다면 얼마의 용량이 적절한지 알아보기로 하였다. 방법:1) 채취한 후 48시간 경과된 제대혈에 대한 분석: 15례의 제대혈을 채취하여 채취 직후와 48시간 후에 10% pentastarch로 적혈구를 분리한 다음, 총유핵세포수와 CD34+ 세포수를 측정하여 수득률을 비교하였다. 48시간이 경과한 검체에 대하여 urokinase는 제대혈 분리 30분 전에 첨가하였으며, urokinase를 첨가하지 않은 군과 urokinase 5,000 IU/mL, 10,000 IU/mL, 50,000 IU/mL을 첨가한 네군으로 나누어 각각의 수득률을 비교 분석하였다. 2) 채취한 후 24시간이내의 제대혈에 대한 분석: 12례의 제대혈을 채취한 직후에 적혈구를 분리하여 총유핵세포수와 CD34+ 세포수, CFU-GM 집락수를 측정하였다. 동일한 검체를 6시간, 12시간, 24시간 동안 실온에 방치한 후 상기 실험 결과 가장 효과적인 용량의 urokinase를 첨가한 군과 첨가하지 않은 군으로 나누어 각각 적혈구를 분리한 다음, 총유핵세포수와 CD34+ 세포수, CFU-GM 집락수를 측정 비교하였다. 결과:1) 제대혈 채취 48시간 후에 urokinase를 첨가하지 않은 경우와 urokinase 5,000 IU/mL를 첨가한 경우 총유핵세포수의 차이가 없었지만, urokinase 10,000 IU/mL, 50,000 IU/mL를 첨가한 경우에는 urokinase를 첨가하지 않은 경우에 비하여 총유핵세포수의 의미있는 증가를 보였다(P=0.0024, P=0.0009). 2) 제대혈 채취 48시간 후에 urokinase 5,000 IU/mL이나 50,000 IU/mL를 첨가한 경우에는 urokinase를 첨가하지 않은 경우에 비하여 CD34+ 세포수의 차이가 없었지만, urokinase 10,000 IU/mL를 첨가한 경우에는 urokinase를 첨가하지 않은 경우에 비하여 CD34+ 세포수의 의미있는 증가를 보였다(P=0.0402). 3) Urokinase 10,000 IU/mL를 첨가하였던 군이나 첨가하지 않았던 군 모두에서 제대혈 채취 즉시 적혈구를 분리하였던 경우에 비하여 6시간, 12시간, 24시간이 경과할수록 총유핵세포수, CD34+ 세포수, CFU-GM 집락수가 약간씩 감소하였으나 시간경과에 따른 통계적 차이는 없었다. 또한 제대혈 채취 24시간 이내에는 각 시간대별로 urokinase 10,000 IU/mL 첨가 유무에 따른 총유핵세포수, CD34+ 세포수, CFU-GM 집락수의 통계적 차이를 나타내지 않았다. 결론:채혈한지 48시간 경과된 제대혈을 냉동 보관해야 하는 경우에는 urokinase 10,000 IU/mL를 첨가하고 30분 후에 적혈구를 분리하는 것이 유핵세포와 CD34+ 세포의 수득률을 높일 수 있는 방법이며, 24시간 이내에 적혈구를 분리하는 경우에는 urokinase를 첨가할 필요가 없을 것으로 생각된다. Background:We assessed whether the urokinase could increase the yield of progenitor cells during processing in elapsed, even anticoagulated, cord blood after collection, and also determined the optimal dosage of urokinase. Methods:Twenty-seven cord blood samples were collected with ACD-coated syringes from umbilical cord vein after full-term vaginal delivery, and red cells were depleted with 10% pentastarch. We assessed the effect and optimal dosage of urokinase by comparing total nucleated cell (TNC) counts and CD34+ cell counts between fresh and 48 hour-elapsed cord bloods. The urokinase was administered to the 48 hour-elapsed cord bloods 30 minutes before separation as the dose of 0 IU/mL, 5,000 IU/mL, 10,000 IU/mL and 50,000 IU/mL, respectively. Thereafter, by using the most effective dosage of urokinase, we also assessed the effect of urokinase in the 6, 12 and 24 hour-elapsed cord bloods. Results:The TNC counts after separation in 48 hour-elapsed cord bloods were significantly higher in 10,000 IU/mL and 50,000 IU/mL of urokinase treated samples than untreated and 5,000 IU/mL treated samples. The CD34+ cell counts were significantly higher in 10,000 IU/mL of urokinase treated samples than untreated and 5,000 or 50,000 IU/mL treated samples. In 6, 12 and 24 hour-elapsed cord bloods, however, there were no significant differences of TNC count, CD34+ cell count and CFU-GM count between 10,000 IU/mL of urokinase treated samples and untreated samples . Conclusion: The addition of 10,000 IU/mL of urokinase before separation of 48 hour-elapsed, even anticoagulated, cord bloods could increase the yield of progenitor cells. However, there are no advantage of urokinase for processing of cord bloods not elapsed 24 hours after collection.

REGULATORY ROLE OF PKC ON THE NF-κB SIGNALING THROUGH IKK-γ AND HSP90 COMPLEX IN COLONIC EPITHELIAL CELLS

Park, Kyeong Ah,Byun, Hee Sun,Won, Minho,Yang, Keum-Jin,Shin, SangHee,Piao, Longzhen,Kim, Jin Man,Woon, Wan-Hee,Park, JongSun,Seok, Jeong Ho,Hur, Gang Min 충남대학교 형질전환복제돼지연구센터 2007 논문집 Vol. No.10

Integrative molecular profiling identifies a novel cluster of estrogen receptor‐positive breast cancer in very young women

Park, Charny,Yoon, Kyong‐,Ah,Kim, Jihyun,Park, In Hae,Park, Soo Jin,Kim, Min Kyeong,Jang, Wooyeong,Cho, Soo Young,Park, Boyoung,Kong, Sun‐,Young,Lee, Eun Sook John Wiley and Sons Inc. 2019 Cancer Science Vol.110 No.5

<P>Very young breast cancer patients are more common in Asian countries than Western countries and are thought to have worse prognosis than older patients. The aim of the current study was to identify molecular characteristics of young patients with estrogen receptor (ER)‐positive breast cancer by analyzing mutations and copy number variants (CNV), and by applying expression profiling. The whole exome and transcriptome of 47 Korean young breast cancer (KYBR) patients (age <35) were analyzed. Genomic profiles were constructed using mutations, CNV and differential gene expression from sequencing data. Pathway analyses were also performed using gene sets to identify biological processes. Our data were compared with young ER+ breast cancer patients in The Cancer Genome Atlas (TCGA) dataset. <I>TP53</I>,<I>PIK3CA</I> and <I>GATA3</I> were highly recurrent somatic mutation genes. APOBEC‐associated mutation signature was more frequent in KYBR compared with young TCGA patients. Integrative profiling was used to classify our patients into 3 subgroups based on molecular characteristics. Group A showed luminal A‐like subtype and IGF1R signal dysregulation. Luminal B patients were classified into groups B and C, which showed chromosomal instability and enrichment for APOBEC3A/B deletions, respectively. Group B was characterized by 11q13 (CCND1) amplification and activation of the ubiquitin‐mediated proteolysis pathway. Group C showed 17q12 (ERBB2) amplification and lower ER and progesterone receptor expression. Group C was also distinguished by immune activation and lower epithelial‐mesenchyme transition (EMT) degree compared with group B. This study showed that integrative genomic profiling could classify very young patients with breast cancer into molecular subgroups that are potentially linked to different clinical characteristics.</P>

Reduction of Bacterial Mutagenesis of 2-Amino-3-Methylimidazo[4,5-f]quinoline by S-9 Fraction from Mice Treated with Conjugated Linoleic Acid (CLA)

Park, Kyung-Ah,Kim, Seck-Jong,Park, Soo-Jahr,Park, Gu-Boo,Lim, Dong-Kil,Bahn, Kyeong-Nyeo,Cho, Yong-Un,Park, Jung H.Y.,Pariza, Michael W.,Ha, Yeongl-Lae The Korean Society of Food Science and Nutrition 2001 Preventive Nutrition and Food Science Vol.6 No.1

Conjugated linoleic acid (CLA), when incorporated into mouse liver microsomal membranes, selectively inhibits the mutagenesis of 2-amino-3-methylimidazo[4,5-f] quinoline (IQ). Nine-week old female ICR mice were given (p.o.) 0.1 mL olive oil alone (control), 0.1 mL olive oil plus 0.1 mL linoleic acid, or 0.1 mL olive oil plus 0.1 mL CLA, twice weekly for four weeks. The animals were then sacrificed and liver S-9 fractions were prepared. Activation of IQ for mutagenesis by the liver S-9 from CLA-treated mice was significantly reduced in comparison wit liver S-9 from control or linolic acid-treated mice. By contrast, the activation of 7,12-dimethylbenz[a] anthracene (DMBA) and benzo[a] pyrene (BP) was unaffected. Hence, CLA incorporated into phospholipids may selectively affect cytochrome P450 isozymes responsible for activating IQ, but not those which activate BP or DMBA. The addition of free CLA or the methyl esters of CLA, linoleic acid, or oleic acid, to control S-9 inhibited the activation of all three mutagens (IQ, BP, and DMBA).

Reduction of Bacterial Mutagenesis of 2 - Amino - 3 - Methylimidazo[4,5 - f]quinoline by S-9 Fraction from Mice Treated with Conjugated Linoleic Acid (CLA)

Kyung-Ah Park,Seck-Jong Kim,Sook-Jahr Park,Gu-Boo Park,Dong-Kil Lim,Kyeong-Nyeo Bahn,Yong-Un Cho,Jung H.Y. Park,Michael W. Pariza,Yeong-Lae Ha 한국식품영양과학회 2001 Preventive Nutrition and Food Science Vol.6 No.1

Conjugated linoleic acid (CLA), when incorporated into mouse liver microsomal membranes, selectively inhibits the mutagenesis of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ). Nine-week old female ICR mice were given (p.o.) 0.1 mL olive oil alone (control), 0.1 mL olive oil plus 0.1 mL linoleic acid, or 0.1 mL olive oil plus 0.1 mL CLA, twice weekly for four weeks. The animals were then sacrificed and liver S-9 fractions were prepared. Activation of IQ for mutagenesis by the liver S-9 from CLA-treated mice was significantly reduced in comparison with liver S-9 from control or linoleic acid-treated mice. By contrast, the activation of 7,12-dimethylbenz[a]anthracene (DMBA) and benzo[a]pyrene (BP) was unaffected. Hence, CLA incorporated into phospholipids may selectively affect cytochrome P450 isozymes responsible for activating IQ, but not those which activate BP or DMBA. The addition of free CLA or the methyl esters of CLA, linoleic acid, or oleic acid, to control S-9 inhibited the activation of all three mutagens (IQ, BP, and DMBA).

Association of polymorphisms in thromboxane A2 receptor and thromboxane A synthase 1 with cerebral infarction in a Korean population

( Sun Ah Park ),( Byung Lae Park ),( Jeong Ho Park ),( Tae Kyeong Lee ),( Ki Bum Sung ),( You Kyoung Lee ),( Hun Soo Chang ),( Choon Sik Park ),( Hyoung Doo Shin ) 생화학분자생물학회 2009 BMB Reports Vol.42 No.4

Evaluation of the Effects of Euglena gracilis on Enhancing Immune Responses in RAW264.7 Cells and a Cyclophosphamide-Induced Mouse Model

Jo Kyeong Ah,Kim Kyeong Jin,Park Soo-yeon,Jeon Jin-Young,Hwang Ji Eun,Kim Ji Yeon 한국미생물·생명공학회 2023 Journal of microbiology and biotechnology Vol.33 No.4

In this study we evaluated the immune-enhancing effects of β-glucan, the main component of Euglena gracilis (Euglena), and Euglena on inflammatory factor expression in RAW264.7 macrophages and ICR mice with cyclophosphamide-induced immunosuppression. Macrophages were treated with βglucan or Euglena for 48 h. The β-glucan and Euglena groups exhibited higher levels of inducible nitric oxide synthase, nitric oxide, and tumor necrosis factor (TNF)-α than the control (vehicle alone) group. Animals were fed saline and β-glucan (400 mg/kg body weight (B.W.)) or Euglena (400 or 800 mg/kg B.W.) for 19 days, and on days 17–19, cyclophosphamide (CCP, 80 mg/kg B.W.) was administered to induce immunosuppression in the ICR mouse model. CCP reduced the body weight, spleen index, and cytokine expression of the mice. To measure cytokine and receptor expression, splenocytes were treated with concanavalin A (ConA) or lipopolysaccharide (LPS) as a mitogen for 24 h. In vivo, ConA stimulation significantly upregulated the expression of interferon (IFN)-γ, interleukin (IL)-10, IL-12 receptor β1, IL-1β, and IL-2 in splenocytes from the β-glucan- or Euglena-treated groups compared with those in the splenocytes from the CCP-treated group; LPS stimulation increased the levels of the cytokines TNF-α, IL-1β, and IL-6 in splenocytes from the β-glucan- or Euglena- treated groups compared with those from the CCP-treated group, but most of these differences were not significant. These results demonstrate the effect of Euglena in ameliorating macrophages and immunosuppression in CCP-treated mice. Thus, Euglena has the potential to enhance macrophageand splenocyte- mediated immune-stimulating responses.

황칠나무 잎 추출물의 세포 항산화 활성과 미백활성 측정

박수아 ( Park Su Ah ),박준 ( Jun Park ),박찬일 ( Chan Il Park ),지영종 ( Young Jong Jie ),황윤찬 ( Yun Chan Hwang ),김용현 ( Yong Hyun Kim ),전소하 ( So Ha Jeon ),이혜미 ( Hye Mi Lee ),하지훈 ( Ji Hoon Ha ),김경진 ( Kyeong Jin Ki 한국미생물생명공학회(구 한국산업미생물학회) 2013 한국미생물·생명공학회지 Vol.41 No.4

본 연구에서는 황칠나무 잎 추출물의 HaCaT 세포에서의 항산화 활성과 B16F1 melanoma 세포에서의 미백활성을 측정하였다. HaCaT 세포를 이용한 실험에서, 황칠나무 잎 추출물의 에틸아세테이트 분획과 아글리콘 분획은 각각 50 및 25 μg/ml의 농도 이하에서 독성을 나타내지 않았다. UVB 800 mJ/cm2를 HaCaT 세포에 조사하였을 때, 황칠나무 잎 추출물은 농도 의존적으로 자외선으로부터 세포를 보호하였다. 10 mM의 H2O2 및 4 μM의 rose bengal을 HaCaT 세포에 처리하였을 때, 에틸아세테이트 분획(6.25~50 μg/ml) 및 아글리콘 분획(6.25~25 μg/ml)은 우수한 세포 보호 효과를 나타내었다. 황칠나무 잎 추출물의 B16F1 melanoma 세포에서의 미백활성을 측정한 결과, 미백제로 알려진 알부틴 보다 더 우수한 멜라닌 합성 저해 활성을 보였다. 이상의 결과들은 황칠나무 잎 추출물이 ROS에 대항하여 세포를 보호함으로써 생체계, 특히 태양 자외선에 노출된 피부에서 세포 보호제 및 천연항산화제로서 작용할 수 있음을 가르키며, α-MSH로 유도된 멜라닌 생합성 저해 효과로부터 황칠나무 잎 추출물이 새로운 미백 화장품의 원료로써 이용 가능함을 알 수 있다. In this study, we investigated the antioxidant activities on HaCaT and the whitening effects on B16F1 melanoma cells of Dendropanax morbifera leaf extract. In an antioxidative activity assay using HaCaT cells, the ethyl acetate (50 μg/ml) and aglycone fractions (25 μg/ml) of the D. morbifera leaf extract didn`t exhibit any characteristics of cytotoxicity. When HaCaT cells were exposed to a single large dose (800 mJ/cm2) of UVB, the extracts protected the cells against UVB radiation. When HaCaT cells were treated with 10 mM H2O2 and 4 μM rose bengal, the ethyl acetate (6.25~50 μg/ml) and aglycone (6.25~25 μg/ml) fractions protected the cells against oxidative damage in a concentration dependent manner. When the whitening effects of D. morbifera leaf extract were tested in melanoma B16/F1 cells treated with the a-melanocyte stimulating hormone (α-MSH), the extracts inhibited α-MSH-stimulated intra/extracellular melanogenesis in a concentration dependent manner. The inhibitory effects of the ethyl acetate and aglycone fractions of D. morbifera leaf extract were 21% and 44% at 25 μg/ml, respectively. Both are more effective than arbutin (15% at 25 μg/ml) which is known as a whitening agent. These results indicate that fractions of the D. morbifera leaf can function as cell protectants and natural antioxidants in biological systems, particularly skins exposed to UV radiation by quenching and/or scavenging 1O2 and other ROS, and protecting cells against ROS. In addition, fractions of the D. morbifera leaf can be applied to new whitening cosmetics because of their inhibitory effects on α-MSH stimulated melanogenesis in B16F1 melanoma cells.

디젤분진이 백서 뇌에 미치는 영향 : Nitric Oxide 및 Nitric Oxide Synthase 아형 발현

박선아,장안수,이보람,박정호,양광익,이태경,박춘식,성기범,안무영 순천향대학교 2006 Journal of Soonchunhyang Medical Science Vol.12 No.1

Background: The possible neurotoxic effect of diesel exhaust particles (DEP), a particulate material from an automobile engine and toxic air pollutant, has been suggested. However, the investigations about it have been rare. Objectives: To examine the possible harmful effect of the inhaled DEP on nervous system we focused on the expression of nitric oxide synthase (NOS) isofonns and nitric oxide (NO) level in the rat brain. Methods: The morphological analysis was performed using neuronal and microglial markers eight days after DEP exposure through nasal cannula-route. In addition, the expression of three NOS isoforms was evaluated by western blot. Nithte and nitrate, a major NO metabolites, were measured using Griess method. Results: We did not find any morphological changes after DEP exposure in terms of the expression of neuronal and microglial markers. And the expression of inducible NOS, neuronal NOS, and endothelial NOS was not altered. There was no change in any of the level of nitrate and nitrite, major NO metabolites. Conclusion: In contrast to the response of lung to DEP, the brain did not show any changes in the level of NOS isoforms, nitrate, or nitrite in this model, It suggests that short-term DEP inhalation may not result in morphological change and alter NO pathway in the brain.

Trends in hospital visits and healthcare costs of gout and seropositive rheumatoid arthritis in Korea from 2010 to 2017 using National Healthcare Claims

Kyeong Min Son,Ju-Ryoung Kim,Hang A Park,Hyun Ah Kim 대한내과학회 2022 The Korean Journal of Internal Medicine Vol.37 No.3

Background/Aims: We examined temporal trends in the rate of gout and seropositive rheumatoid arthritis (RA) hospital visits and healthcare costs in Korea. Methods: We conducted a serial cross-sectional analysis of Korean national healthcare claims. We calculated the annual increase in hospital visits (emergency department [ED] visits, outpatient visits, and hospitalizations) and total healthcare costs per visit. Results: From 2010 to 2017, the annual rates of ED visits, outpatient visits, and hospitalizations for gout increased from 6.28 to 21, from 638.38 to 1059.55, and from 12.37 to 15.6 per 100,000 persons, respectively. Before 2013, ED visits for gout were most common in patients over 70 years old, but they were most common in those aged between 30 and 49 years after 2013. The number of patients with ED visits, outpatient visits, and hospitalizations for RA from 2010 to 2017 increased from 1.25 to 1.87, from 219.04 to 307.49 and from 8.44 to 12.32 per 100,000 persons, respectively. However, there was no increase in the prevalence of ED visits for RA in any age group except for those older than 70 years. The cost per ED visit for gout significantly decreased from 496.3 to 273.6 US dollar during the study period. There was no significant change in the cost per ED visit for RA between 2010 and 2017. Conclusions: There was a large increase in ED visits for gout during the study period. Further studies are needed to analyze the reason behind increased ED visits for gout and suggest ways on how to improve gout care.